The FDA has defended its decision to issue a refusal-to-file (RTF) letter for Moderna's new mRNA-based influenza vaccine, claiming the company had not used an appropriate control group in its pivotal ...
Andrea Riquier is a former Staff Writer at Forbes Advisor. She is a New York-based writer covering mortgages and the housing market. She was previously at Dow Jones MarketWatch, on the housing market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results